To assess whether rituximab treatment affected on the prognostic impact of CD5 expression, CD43 expression, and CD5/CD43 coexpression in DLBCL, the patients were divided into CHOP and R‐CHOP treatment groups. This evidence concerns the gene SPN and diffuse large B-cell lymphoma.